Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial

Abstract excerpt

•OReO is the first study to show that maintenance olaparib rechallenge provides a PFS benefit in relapsed ovarian cancer.•Statistically significant PFS benefit is seen with olaparib rechallenge over placebo independent of BRCA mutation status.•A proportion of the OReO population was still progression free at 1 year.•No new safety signals were observed with maintenance olaparib rechallenge.•Further investigation...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Advanced Breast Cancer Therapies
• Share to Ovarian cancer diagnosis and treatment
• Share to PARP inhibition in cancer therapy